| __timestamp | Gilead Sciences, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2854000000 | 7459000 |
| Thursday, January 1, 2015 | 3014000000 | 11831000 |
| Friday, January 1, 2016 | 5098000000 | 25705000 |
| Sunday, January 1, 2017 | 3734000000 | 46181000 |
| Monday, January 1, 2018 | 5018000000 | 59497000 |
| Tuesday, January 1, 2019 | 9106000000 | 65003000 |
| Wednesday, January 1, 2020 | 5039000000 | 74506000 |
| Friday, January 1, 2021 | 5363000000 | 126006000 |
| Saturday, January 1, 2022 | 4977000000 | 126215000 |
| Sunday, January 1, 2023 | 6923000000 | 120161000 |
| Monday, January 1, 2024 | 5907000000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Gilead Sciences, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting yet intriguing R&D strategies.
Gilead Sciences has consistently invested heavily in R&D, with expenditures peaking in 2019 at nearly 9 billion dollars. This represents a staggering 219% increase from their 2014 investment. Such robust funding underscores Gilead's commitment to pioneering treatments and maintaining its leadership in the biotech sector.
In contrast, Protagonist Therapeutics has shown a steady increase in R&D spending, growing by over 1,500% from 2014 to 2023. This growth trajectory highlights the company's strategic focus on innovation and its potential to disrupt the market with novel therapies.
As these companies continue to invest in R&D, the future of biotechnology looks promising, with potential breakthroughs on the horizon.
Johnson & Johnson vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Pfizer Inc. and Gilead Sciences, Inc.
Gilead Sciences, Inc. vs GSK plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Gilead Sciences, Inc. and Verona Pharma plc
Comparing Innovation Spending: Gilead Sciences, Inc. and Alkermes plc
Gilead Sciences, Inc. vs Geron Corporation: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How Genmab A/S and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Investment: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc.
R&D Spending Showdown: Ionis Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Mesoblast Limited: Who Invests More in Innovation?
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.